StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Premarin Family [legacy through FY24] by Year

Premarin Family (conjugated estrogens) [legacy through FY24] — U.S. revenues ($M) ($M)

QuarterlyAnnual

Pfizer Premarin Family [legacy through FY24]: $341M in FY2024, down 5.5% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2024
341
Period ended Dec 31, 2024
Change on a year earlier
-5.5%
361 in FY2023
History
9 years
Since FY2016
Sources
8
Documents cited below

Where the FY2024 figure comes from

“|| Premarin family | 380 | 397 | (4%) | (4%) | 341 | 361 | (5%) | 39 | 36 | 8% | 9%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPremarin Family (conjugated estrogens) [legacy through FY24] — U.S. revenues ($M) ($M)Year on yearSource
FY2024Dec 31, 2024341-5.5%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2023Dec 31, 2023361+1,800.0%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 202219-5.0%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2021Dec 31, 202120-9.1%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2020Dec 31, 202022+4.8%Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2019Dec 31, 201921-8.7%Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
FY2018Dec 31, 201823-97.5%Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗
FY2017Dec 31, 2017921-3.7%Form 8-K (Earnings / Guidance Release) (pfe-12312018xex99.htm, filed 2019-01-29) ↗
FY2016Dec 31, 2016956–Form 8-K (Earnings / Guidance Release) (pfe-12312017xex99.htm, filed 2018-01-30) ↗

Breakdown

What makes up premarin Family [legacy through FY24]

Cite this data

StockData. (2026). Pfizer Premarin Family [legacy through FY24] ($M), annual FY2016–FY2024 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/premarin-leg-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.